Lilly inks $2.75B AI drug deal
Eli Lilly signed a $2.75 billion deal with Insilico Medicine to accelerate AI‑driven drug discovery, underscoring big pharma’s willingness to deploy generative models at scale in R&D. The size of the agreement highlights rising demand for researchers who combine ML, chemistry/biology literacy, and experimental design. (mugglehead.com) (pharmiweb.com)
Lilly will pay Insilico $115 million upfront, with additional development, regulatory and commercial milestone payments and tiered royalties, and Insilico granted Lilly an exclusive worldwide license to develop, manufacture and commercialize certain preclinical oral therapeutics. (PR Newswire; EurekAlert). The agreement expands a relationship that began in 2023 when Lilly first licensed Insilico’s Pharma.AI suite and follows a November 10, 2025 expansion into a joint research collaboration between the two companies. (PharmExec; Insilico press release). Insilico cites a Pharma.AI platform as its core stack, launched an agentic-AI feature called PandaClaw on March 23, 2026, and publishes multimodal foundation models such as Nach01 designed for molecule design and prediction. (PR Newswire; Microsoft blog; Insilico website). Insilico’s careers page lists “300+ top scientists” and active openings for roles including machine learning engineers, bioinformatics engineers and LLM architect positions across the U.S., Greater China, Canada and the UAE. (Insilico careers). Lilly’s job portals and public listings show dozens of open roles tied to AI and discovery—Indeed aggregates 20–48 AI-related openings while Lilly’s career site and recent postings include forward‑deployed AI engineering and computational chemistry advisor roles. (Indeed; Lilly careers; BioSpace job listing). Insilico’s Hong Kong‑listed shares jumped intraday by about 15% on the announcement, and industry coverage linked the transaction to a broader strategic push by big pharma to secure AI‑native discovery pipelines. (Bloomberg; GenEngNews). Industry analyses and surveys flag a persistent pharma AI skills gap—one 2025 analysis cited a GlobalData finding that 49% of respondents named skills shortages as the top barrier and a Pistoia Alliance survey showed 44% reporting lack of skills—underscoring competition for candidates who combine ML expertise with chemistry and biology domain knowledge. (IntuitionLabs report; PharmTech; PharmaVoice).
